Moderna (MRNA) shares extended gains on Aug. 25 after Wolfe Research upgraded the biotech giant, citing recent positive developments surrounding its personalized cancer vaccine.
Analyst Alexandria Hammond now rates MRNA at “Peer Perform,” albeit without a particular price target that explains how high the stock could fly in the second half of 2026.